Chemed Co. (CHE) Receives Average Rating of “Hold” from Analysts

Chemed Co. (NYSE:CHE) has earned an average rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $236.00.

CHE has been the topic of several research reports. Oppenheimer increased their price target on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price on the stock in a research report on Thursday, November 2nd. Royal Bank of Canada raised their target price on shares of Chemed to $232.00 and gave the stock a “sector perform” rating in a research report on Tuesday, October 31st. ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, KeyCorp restated a “hold” rating on shares of Chemed in a research report on Friday, October 27th.

Shares of Chemed (NYSE CHE) opened at $253.43 on Friday. The company has a market cap of $4,120.00, a P/E ratio of 56.44 and a beta of 1.13. Chemed has a 1 year low of $167.97 and a 1 year high of $275.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.

In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of Chemed stock in a transaction on Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the transaction, the vice president now owns 3,334 shares in the company, valued at approximately $833,500. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Nicholas Michael Westfall sold 10,000 shares of Chemed stock in a transaction on Monday, November 13th. The shares were sold at an average price of $231.00, for a total transaction of $2,310,000.00. Following the completion of the transaction, the insider now owns 13,351 shares in the company, valued at approximately $3,084,081. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,529 shares of company stock worth $7,446,966. 4.90% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in CHE. IFP Advisors Inc boosted its holdings in shares of Chemed by 1,504.5% in the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after purchasing an additional 662 shares during the last quarter. MCF Advisors LLC acquired a new position in shares of Chemed in the 3rd quarter valued at $152,000. Hengehold Capital Management LLC acquired a new position in shares of Chemed in the 4th quarter valued at $203,000. Magnetar Financial LLC acquired a new position in shares of Chemed in the 3rd quarter valued at $207,000. Finally, D.A. Davidson & CO. acquired a new position in shares of Chemed in the 4th quarter valued at $209,000. Institutional investors own 97.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/11/chemed-co-che-receives-average-rating-of-hold-from-analysts.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply